Bonn-based biotech company Neuway Pharma and Munich-based chemical company Wacker have launched a research project to identify and manufacture RNA-based actives for the treatment of diseases of the central nervous system (CNS).   They will make use of Neuway’s protein-based drug delivery technology EnPC, which allows for targeted drug delivery via the blood-brain barrier into the CNS.   Under the collaboration agreement, Neuway Pharma and Wacker will jointly research active substances based ...